Based in Oslo, Norway, Lytix Biopharma ASA is a clinical-stage biotechnology firm dedicated to advancing innovative immunotherapies for cancer treatment. Its primary drug candidate, LTX-315, is an oncolytic molecule currently undergoing Phase II clinical trials. This therapy is formulated for intratumoral injection, aiming to provide localized treatment for solid tumors. Additionally, Lytix Biopharma is developing LTX-401, another oncolytic molecule in its preclinical phase, specifically designed to target deep-seated cancerous lesions, including those found in liver cancer. The company was established in 2003.
Show more...
FAQ
Lytix Biopharma AS 今天的股價是多少?▼
6BG.STU 目前價格為 €0.73 EUR,過去 24 小時上漲了 +0.55%。在圖表上更密切關注 Lytix Biopharma AS 股價表現。
Lytix Biopharma AS 的股票代號是什麼?▼
根據交易所不同,股票代號可能會有所差異。例如,在 Boerse Stuttgart 交易所,Lytix Biopharma AS 的股票以代號 6BG.STU 進行交易。
Lytix Biopharma AS 的股價在上漲嗎?▼
6BG.STU 股票較上週下跌 -0.54%,本月上漲 +0%,過去一年 Lytix Biopharma AS 上漲 +17.95%。
Lytix Biopharma AS 的市值是多少?▼
今天 Lytix Biopharma AS 的市值為 56.44M
Lytix Biopharma AS 去年的營收是多少?▼
Lytix Biopharma AS 去年的營收為 951,045.51EUR。
Lytix Biopharma AS 去年的淨利是多少?▼
6BG.STU 去年的淨收益為 -8.18MEUR。
Lytix Biopharma AS 會發放股息嗎?▼
是的,6BG.STU 的股息每 年度 發放一次。每股最新股息為 0.76 EUR。截至今日,股息殖利率(FWD)% 為 0%。
Lytix Biopharma AS 有多少名員工?▼
截至 September 07, 2026,公司共有 14 名員工。
Lytix Biopharma AS 位於哪個產業?▼
Lytix Biopharma AS從事於Health & Wellness產業。
Lytix Biopharma AS 何時完成拆股?▼
Lytix Biopharma AS 最近沒有進行任何拆股。
Lytix Biopharma AS 的總部在哪裡?▼
Lytix Biopharma AS 的總部位於 Other 的 Oslo。